How Europe’s New HTA Reality for Biotech Sponsors works

Biotechnology sponsors entering Europe are facing a quieter but more important access shift than many realise.

It is easy to describe this shift as procedural. The European Union has introduced Joint Clinical Assessment under the EU Health Technology Assessment Regulation. The United Kingdom has launched the MHRA–NICE aligned pathway. Regulatory and HTA processes are moving closer together. Timelines are becoming more coordinated. Dossiers need to be prepared earlier.

All of that is true.

But it misses the deeper point.

Europe is not simply asking biotech companies to prepare documents faster. It is asking whether the evidence has been designed properly in the first place.

That is a much harder test.

For years, many companies could think about Europe in sequence. First, secure regulatory approval. Then, once the product was authorised, begin the serious work of health technology assessment, reimbursement, pricing, payer evidence and national access. That model was never ideal, but it was workable enough for many sponsors. It allowed market access teams to arrive late and attempt to translate a regulatory evidence package into a reimbursement argument.

That space is narrowing.

The new European environment rewards companies that understand access early. It penalises companies that treat HTA as a post-approval exercise. It exposes the difference between a product that is approvable and a product that is access-ready.

That distinction now matters more than ever.

What has changed?

The EU Health Technology Assessment Regulation, formally Regulation (EU) 2021/2282, entered into application on 12 January 2025. The European Commission’s implementation page explains that the Regulation applies from that date and establishes a new framework for EU-level cooperation on health technology assessment.

The first wave is focused on new medicines for cancer treatment and advanced therapy medicinal products. The European Commission’s page on Joint Clinical Assessments states that, from 12 January 2025, new cancer medicines and advanced therapy medicinal products are subject to JCA. The European Medicines Agency also explains that the new rules initially apply to new active substances to treat cancer and to all ATMPs, with later expansion to orphan medicines and all centrally authorised medicines. The EMA summary is available here: New EU rules for health technology assessments become effective.

In the UK, the MHRA–NICE aligned pathway is designed to bring regulatory and NICE decision-making closer together. GOV.UK describes the pathway as a mechanism to bring NICE decisions forward to align with MHRA decisions, with the aim of getting new medicines to patients three to six months sooner. NICE has also described the pathway as fully open from 1 April 2026 in its article, MHRA–NICE pathway opens for business.

These are important reforms.

But they should not be misunderstood.

The EU Joint Clinical Assessment is not European reimbursement. It does not decide price. It does not decide budget impact. It does not decide whether a hospital, insurer or national health system will pay for the product. Those decisions remain national. France, Germany, Italy, Spain, England, Scotland, the Nordic countries and other European systems will still ask their own questions, apply their own methods and make their own access decisions.

Likewise, the UK aligned pathway does not make NICE and MHRA the same organisation. MHRA still assesses quality, safety and efficacy. NICE still assesses clinical and cost effectiveness. The pathway changes the timing and coordination. It does not remove the difference between approval and value.

This is why the new environment is so demanding.

The processes are closer together, but the questions remain different.

Approval is not access

The central mistake is to assume that regulatory success naturally leads to reimbursement success.

It may not.

A product can be scientifically exciting, clinically active and capable of receiving marketing authorisation, yet still be difficult to reimburse. That is not because HTA bodies are hostile to innovation. It is because reimbursement is not a repeat of regulatory review. It asks a different question.

Regulators ask whether the product has a positive benefit–risk profile.

HTA bodies ask what the product adds, compared with the relevant standard of care, in the relevant population, using outcomes that matter to patients and health systems, at a cost that can be justified.

That difference sounds simple. In practice, it is often where access fails.

A trial comparator may be acceptable for regulatory purposes but misaligned with European clinical practice. The studied population may be broader than the population in which the product is likely to be reimbursed. The endpoint may demonstrate biological or clinical activity but not translate cleanly into patient-relevant value. Survival data may be immature. Quality-of-life data may be weak. Subgroup claims may be plausible but underpowered. The evidence may not support a credible indirect comparison. The economic model may depend on assumptions that the clinical data cannot sustain.

None of these problems can be solved easily at the point of dossier submission.

They are evidence architecture problems.

They begin much earlier.

The real issue is readiness

This is why the most important word in European biotech access is not speed.

It is readiness.

Readiness means more than having a regulatory dossier and an HTA dossier prepared at the same time. It means that the clinical development programme has been designed to answer the questions that will determine access.

Is the comparator relevant to European standard of care?

Is the population aligned with the likely reimbursed population?

Are the endpoints meaningful for HTA, not only for approval?

Can the evidence support claims about relative effectiveness?

Can quality of life, function, treatment burden or survival benefit be demonstrated convincingly?

Is indirect comparison feasible?

Can the data support economic modelling?

Is uncertainty acknowledged, quantified and managed?

Is there a credible plan to reduce uncertainty after launch?

These are not cosmetic questions. They shape whether a product moves from authorisation to reimbursement, from reimbursement to adoption, and from adoption to real patient access.

Parallel review does not create parallel readiness.

It only reveals whether readiness was built early enough.

PICO is where the value question begins

In the EU JCA process, the PICO framework — population, intervention, comparator and outcomes — is central. It may sound technical, but it is not a bureaucratic detail. PICO defines the value question.

A sponsor may believe it has generated excellent evidence. But if the population is not the one European assessors care about, the evidence may lose relevance. If the comparator does not reflect European practice, the relative benefit may be difficult to interpret. If the outcomes do not capture what matters to patients, clinicians or payers, the claim may be weakened. If the treatment pathway differs across countries, national bodies may still ask for additional interpretation.

For US biotech companies, this is especially important.

A development programme shaped around FDA expectations may not automatically answer European HTA questions. FDA logic and European reimbursement logic overlap, but they are not the same. Safety and efficacy are necessary. They are not sufficient.

European systems want to know what changes in the pathway. They want to know which patients benefit most. They want to know whether the benefit is clinically meaningful, durable and relevant to the health system. They want to know what uncertainty remains and who carries the risk of that uncertainty.

The earlier these questions are asked, the better the development programme becomes.

The later they are asked, the more they become damage control.

Indirect comparison cannot be a rescue exercise

One of the most underestimated access problems is indirect comparison.

In oncology, rare diseases and advanced therapies, direct head-to-head evidence against every relevant European comparator is often unavailable. That is understandable. Trials are difficult. Populations are small. Standards of care change. Ethical and operational constraints are real.

But HTA bodies still need to understand relative effectiveness.

That means sponsors often rely on indirect treatment comparisons, network meta-analysis, matching-adjusted indirect comparison, simulated treatment comparison, external control arms or real-world evidence. These methods can be valuable. They can also be fragile.

The EU HTA Coordination Group has published a Methodological Guideline for Quantitative Evidence Synthesis: Direct and Indirect Comparisons, alongside a Practical Guideline for Quantitative Evidence Synthesis. These documents are important because they show that indirect comparison is not simply a statistical appendix. It is a methodological question at the heart of relative effectiveness assessment.

The credibility of an indirect comparison depends on assumptions: similarity, exchangeability, transitivity, outcome consistency, follow-up comparability, treatment-line alignment and the availability of relevant data. If these assumptions are not considered until after the pivotal trial has reported, the sponsor may discover that the evidence network is weak, the populations are too different, the outcomes do not align, or the comparator data are unusable.

At that point, statistics cannot repair poor planning.

Indirect comparison should not be treated as a late rescue exercise. It should be considered before trial design, before endpoint selection, before data collection, and before the evidence package is locked.

This is one of the clearest examples of why regulatory and HTA planning must be integrated early. A trial can be internally coherent and still be externally difficult to compare.

The new access problem is uncertainty management

Many of the most innovative biotech products arrive with evidence that is promising but incomplete.

That is particularly true in oncology, rare diseases, cell and gene therapies, and other high-innovation areas. Evidence may be based on single-arm studies, small populations, surrogate endpoints, immature survival data, short follow-up or limited quality-of-life evidence.

This does not mean the product lacks value.

It means the access strategy must explain uncertainty intelligently.

What is known?

What is uncertain?

Why is the uncertainty acceptable?

How does the uncertainty affect the estimate of clinical benefit?

How does it affect cost effectiveness?

How will uncertainty be reduced after launch?

What real-world evidence, registry, managed access agreement or further study will be used to confirm the value proposition?

This is where weaker access strategies often fail. They try to sell certainty where the evidence does not support certainty. A stronger strategy does the opposite. It characterises uncertainty clearly, explains its implications, and proposes a credible route to reduce it.

European payers do not expect perfect evidence in every high-innovation area. But they do expect intellectual honesty, methodological discipline and a plan.

National access still matters

There is another risk in the current discussion: the idea that EU-level HTA somehow simplifies Europe into a single access market.

It does not.

The JCA may reduce duplication in clinical assessment, but national reimbursement decisions remain national. Germany will still have its AMNOG process. France will still assess clinical benefit and improvement in clinical benefit. England will still require cost-effectiveness analysis through NICE. Other systems will still bring their own budget, implementation and procurement realities.

That means the strategic work does not end with JCA.

A sponsor still needs to understand how the European clinical assessment will translate into national value arguments. A relative-effectiveness conclusion that is helpful in one country may not be sufficient in another. A subgroup that is strategically attractive at EU level may need to be reframed nationally. A price that appears defensible in one system may create difficulty in another.

Europe is becoming more coordinated.

It is not becoming uniform.

That distinction is critical.

What biotech sponsors should do before pivotal trial lock

The practical lesson is simple, but demanding.

Biotech sponsors should begin European access planning before the pivotal programme is fixed.

They should map the likely European standard of care and not assume that a global comparator strategy will be enough. They should test whether the likely licensed population and likely reimbursed population are the same. They should examine whether patient-relevant outcomes, quality-of-life data and longer-term follow-up are adequate for HTA. They should think early about indirect comparison feasibility, including whether external datasets will be available and whether outcomes are aligned.

They should build the economic model early enough to identify which clinical assumptions drive value. They should plan real-world evidence not as a publication exercise, but as an uncertainty-reduction strategy. They should prepare for the possibility that national HTA bodies will ask different questions even after an EU-level assessment.

Most importantly, they should stop asking only whether the evidence package can support approval.

They should ask whether it can support access.

Europe is raising the cost of late thinking

The EU HTA Regulation and the MHRA–NICE aligned pathway are sometimes presented as mechanisms for faster access. They may be. Better coordination should reduce unnecessary delay, duplication and uncertainty in the system.

But for sponsors, they also raise the cost of poor preparation.

When regulatory and HTA timelines were further apart, companies had more opportunity to retrofit the access story. That was never ideal, but sometimes it was possible. As timelines converge, the room for late correction becomes smaller. Weak comparator choices, poorly defined populations, inadequate endpoints, immature value arguments and unsupported economic assumptions will become visible earlier.

This is not a reason for pessimism. It is a reason for better science.

The companies that succeed in Europe will not simply be those that file quickly. They will be those that understand the relationship between clinical evidence, regulatory judgement, comparative effectiveness, health economics and national reimbursement from the beginning.

They will design evidence that is not only approvable, but usable.

That is the new European readiness test.

The question is no longer: can the company submit?

The question is: is the evidence access-ready?